Table 1.
Baseline characteristics of the derivation and validation cohorts
| Derivation Cohort (HEAAL) n=3786 | HEAAL missing data: no. (%) | Validation Cohort (SCD-HeFT) n=2521 | SCD-HeFT missing data: no. (%) | |
|---|---|---|---|---|
| Age (yrs): mean ±SD | 64 ± 12 | 0 (0) | 59 ± 12 | 0 (0) |
| Female: n(%) | 1143 (30) | 0 (0) | 588 (23) | 0 (0) |
| Race/Ethnicity: | ||||
| White: n(%) | 2321 (61) | 0 (0) | 1932 (77) | 0 (0) |
| Asian: n(%) | 856 (22) | |||
| Multi: n(%) | 354 (9) | |||
| Hispanic: n(%) | 212 (5) | |||
| Other: n(%) | 103 (3) | |||
| Left ventricular ejection fraction (%): median (IQR) | 33 (27-37) | 1(0.02) | 25 (20-30) | 2(0.1) |
| New York Heart Association Class: | ||||
| I: n(%) | 2 (<0.01) | 1 (0.02) | 0 (0) | |
| II: n(%) | 2657 (69) | 1761 (70) | ||
| III: n(%) | 1152 (30) | 760 (30) | ||
| IV: n(%) | 22 (0.5) | |||
| Ischemic Heart Disease: n(%) | 2456 (64) | 0 (0) | 1305 (52) | 0 (0) |
| Diabetes: n(%) | 1199 (31) | 0 (0) | 767 (30) | 0 (0) |
| Atrial Fibrillation: n(%) | 1070 (28) | 0 (0) | 390 (16) | 0 (0) |
| Stroke: n(%) | 307 (8) | 0 (0) | 166 (7) | 0 (0) |
| Systolic Blood Pressure (mmHg): mean ±SD | 126 ± 18 | 1 (0.02) | 120 ± 20 | 9 (0.4) |
| Heart Rate (bpm): mean ±SD | 73± 12 | 5 (0.1) | 75± 14 | 9 (0.4) |
| Weight (kg): mean ±SD | 76 ± 17 | 5 (0.1) | 88 ± 20 | 0 (0) |
| Serum Sodium (mEq/L): mean ±SD | 140 ± 4 | 16 (0.4) | 139 ± 3 | 20 (0.8) |
| Creatinine (mg/dl): mean ±SD | 1.2 ± 0.3 | 16 (0.4) | 1.2 ± 0.7 | 21 (0.8) |
| ACEi/ARB: n (%) | 3786 (100) | 0 (0) | 2432 (97) | 0 (0) |
| Beta blocker: n (%) | 2758 (72) | 0 (0) | 1738 (69) | 0 (0) |
| Aldosterone antagonist: n (%) | 1436 (38) | 0 (0) | 484 (19) | 1 (<−0.1) |
| Diuretics: n(%) | 3071 (80) | 0 (0) | 2064 (82) | 0 (0) |
| Aspirin: n (%) | 2138 (56) | 0 (0) | 1415 (56) | 0 (0) |
| Statin: n (%) | 1511 (39) | 0 (0) | 965 (38) | 0 (0) |
| Calcium channel Blocker: n (%) | 450 (12) | 0 (0) | 279 (11) | 0 (0) |
| ICD at time of enrollment n(%) | 172 (4.5) | 0 (0) | 0 (0) | 0 (0) |